This is a working overview of human growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
13 December The UK economy shrinks for the second month in a row, with a 0.1% drop in GDP reported for October. The City of London grants planning approval for 1 Undershaft, a new skyscraper that will be tied with the Shard as western Europe's tallest building. 14 December Roisin Quinn, operations director of National Grid plc, confirms that power has been restored to all its customers who experienced outages during Storm Darragh. A number of Irish-themed pubs in the UK have told the BBC they have run out of Guinness after the brewery's owners, Diageo, imposed a limit on supplies in the run up to Christmas. A woman is killed and two men are injured in a shooting in Harlesden, West London. 15 December – UK Foreign Secretary David Lammy says that the British government has made "diplomatic contact" with the Syrian rebel group that overthrew the Assad regime. A £50m humanitarian aid package is announced for vulnerable Syrians. 16 December BBC News reports that Prince Andrew will not join the Royal family at Sandringham for Christmas following revelations about his links to an alleged Chinese spy. Yang Tengbo is named as the alleged Chinese spy with links to Prince Andrew. Archbishop of York Stephen Cottrell, who is to take temporary charge of the Church of England following the resignation of Justin Welby as Archbishop of Canterbury, faces calls for his resignation over his handling of a sexual abuse case while he was Bishop of Chelmsford.
== Healthcare == UPMC Children's Hospital of Pittsburgh Community Health Partnerships, Scotland Certified Health Physicist, United States, a specialist in radiation protection and safety Centre for Health Protection, an agency of Hong Kong Cricohyoidopexy, a surgical procedure
== Views on religion == Crick referred to himself as a humanist, which he defined as the belief "that human problems can and must be faced in terms of human moral and intellectual resources without invoking supernatural authority." He publicly called for humanism to replace religion as a guiding force for humanity, writing:
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.
Sources: en.wikipedia.org
=== Semilente insulin === Semilente insulin was an insulin from the lente family of insulin that was derived from pork. It had smaller crystals than untralente, so it was absorbed faster, and therefore had a shorter duration of action which was similar to that of regular insulin. Like the other lente insulins, it was phased out in the early 2000s. It was produced by Lilly under the name Semilente Iletin I.
Nine mobile detachments (Wuyi, Jiangsu; Putian, Fujian; Guangzhou; Foshan, Guangdong; Mengzi, Yunnan; Nanchong, Sichuan); Two Special Operations detachments (Guangzhou(Snow Leopard Commando Unit) and Huzhou, Zhejiang); Three Transportation detachments (Hefei, Anhui; Mianyang, Sichuan; Linzhi, Tibet); One Engineering/Chemical Defense detachment (Fuzhou, Fujian); One Helicopter detachment with 3 Groups The incumbent Commander is Major General Chen Hongwu, while the Political Commissar is Major General Yang Zhenguo.
=== Meniscus injury === A 2022 review found that in people with meniscus tears, PRP treatment reduced the failure rate of meniscus repair surgery and reduced postoperative pain. However, the review did not find consistent evidence that PRP improved knee function.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.